Capsule Summary Slidesets

Share

Program Content

Activities

  • Dara + Kd in Len-Refractory MM
    Daratumumab, Carfilzomib, and Dexamethasone in Lenalidomide-Refractory Relapsed Myeloma (MMY1001 Subgroup Analysis)
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2018

    Expires: June 02, 2019

  • OPTIMISMM Trial
    OPTIMISMM: Phase III Trial of Pomalidomide, Bortezomib, Low-Dose Dexamethasone vs Bortezomib, Low-Dose Dexamethasone Alone in Lenalidomide-Exposed RRMM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2018

    Expires: June 02, 2019

  • Phase II VenKd for R/R MM
    A Phase II Trial of Venetoclax, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2018

    Expires: June 03, 2019

  • bb2121 in R/R MM
    Anti-BCMA CAR T-Cell Therapy bb2121 in R/R Multiple Myeloma: Updated Phase I Dose-Escalation and Dose-Expansion Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2018

    Expires: June 03, 2019

  • Ivosidenib in R/R AML
    Phase I Study of Ivosidenib, an Investigational IDH Inhibitor, in Relapsed/Refractory IDH1-Mutated Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2018

    Expires: June 03, 2019

  • Ibrutinib/Rituximab in WM
    iNNOVATE (PCYC-1127): Phase III Study of Ibrutinib/Rituximab in Waldenström Macroglobulinemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2018

    Expires: June 03, 2019

  • Moxetumomab in R/R HCL
    Study 1503: Moxetumomab Pasudotox in Heavily Pretreated Relapsed/Refractory Hairy Cell Leukemia
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2018

    Expires: June 04, 2019

  • ZUMA-1 Long-Term Follow-up
    Durability of Response to Axicabtagene Ciloleucel in Patients With Refractory DLBCL: Long-term Follow-up of Phase II ZUMA-1 Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2018

    Expires: June 04, 2019

  • CAPTIVATE Interim Analysis
    Phase II CAPTIVATE: First-line Ibrutinib + Venetoclax in Chronic Lymphocytic Leukemia (Interim Analysis)
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2018

    Expires: June 05, 2019

  • RELEVANCE
    RELEVANCE: Phase III Study of Lenalidomide + Rituximab vs Chemotherapy + Rituximab in Untreated Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2018

    Expires: June 05, 2019

  • ARROW: Kd in R/R MM
    A.R.R.O.W. Phase III Trial of Once- vs Twice-Weekly Carfilzomib + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2018

    Expires: June 06, 2019

  • Venetoclax in Elderly AML
    Phase Ib Study of Venetoclax With Decitabine or Azacitidine in Elderly Patients With Untreated Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2018

    Expires: June 06, 2019

  • BCP-ALL Long-Term Survival
    Long-term Survival With Blinatumomab and Allogeneic HSCT in B-Cell Precursor Acute Lymphoblastic Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2018

    Expires: June 07, 2019

  • ACE-WM-001: Acalabrutinib in WM
    ACE-WM-001: Phase II Study of Acalabrutinib in Patients With Untreated or Relapsed/Refractory Waldenström Macroglobulinemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2018

    Expires: June 10, 2019

  • Carfilzomib R/R MM
    SWOG S1304: Low- vs High-Dose Carfilzomib + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2018

    Expires: June 10, 2019

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen